上海交通大学学报（医学版）

›› 2012, Vol. 32 ›› Issue (5): 674-.doi: 10.3969/j.issn.1674-8115.2012.05.032

• 综述 • 上一篇    下一篇

PI3K/Akt/mTOR信号通路及mTOR抑制剂在泌尿系统肿瘤中的研究进展

宿恒川, 孙福康   

  1. 上海交通大学 医学院附属瑞金医院泌尿外科, 上海 200025
  • 出版日期:2012-05-28 发布日期:2012-06-01
  • 通讯作者: 孙福康, 电子信箱: sunfukang6@sina.com。
  • 作者简介:宿恒川（1987—）, 男, 硕士生；电子信箱: suhengchuan@163.com。
  • 基金资助:

    上海市自然科学基金（10411960000）

Research progress of PI3K/Akt/mTOR signaling pathway and mTOR inhibitors in urologic malignancies

SU Heng-chuan, SUN Fu-kang   

  1. Department of Urology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200025, China
  • Online:2012-05-28 Published:2012-06-01
  • Supported by:

    Shanghai Natural Science Foundation,10411960000

PDF (PC)

1680

摘要：

PI3K/Akt/mTOR信号通路在血管生成、蛋白合成以及细胞生长代谢中发挥着关键作用，在多种实体性恶性肿瘤中已发现该信号通路调节异常。随着PI3K/Akt/mTOR信号通路相关抑制药物的相继问世，尤其是在治疗晚期肾癌中显示出一定的临床疗效，对该通路以及相应抑制药物的深入研究，特别是在泌尿系统肿瘤的应用，成为热点之一。该文总结了PI3K/Akt/mTOR信号通路的发生机制及其在肿瘤形成过程中的作用，并就mTOR抑制剂在泌尿系统肿瘤中的研究进展进行综述。

关键词: PI3K, Akt, mTOR, 信号通路, mTOR抑制剂, 泌尿系统, 肿瘤

Abstract:

PI3K/Akt/mTOR signaling pathway plays a vital role in the angiogenesis, protein synthesis, cell growth and metabolism, and dysregulation of this pathway has been found in many substantive malignant tumors. In recent years, the inhibitors of PI3K/Akt/mTOR signaling pathway have been developed in succession, which have exhibited definite clinical effects on advanced renal cell carcinoma. As a result, further research on this pathway and its inhibitors, particularly their applications in urologic malignancies, has become one of the hot research areas. This paper focuses on the mechanism of PI3K/Akt/mTOR signaling pathway and its roles in the development of tumors, and the research progress of mTOR inhibitors in urologic malignancies is also reviewed.

Key words: PI3K, Akt, mTOR, signaling pathway, mTOR inhibitors, urinary system, tumors